Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Medium materiality6/10

60 Degrees Q2 2026 Results Highlight Limited Revenue Growth and Ongoing Losses

Aug 14, 2026, 3:49 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Small cap biopharma with modest revenue, persistent losses, and liquidity risk; no manufacturing capacity raises burn risk; investors will focus on cash runway and near-term fundraising or licensing outcomes, as seen in similar microcaps reacting to earnings with volatility and potential dilution.

AI summary

What happened, with direct paths to the underlying reporting

60 Degrees reported Q2 2026 net product revenue of $208k, up 106% YoY, but net loss was $2.40M ($0.90 per share). Gross profit was $57k; operating expenses rose to $2.33M. The company cites going-concern risk and lack of manufacturing capacity, while pursuing babesiosis trials and ARAKODA sales for malaria prevention.

Q2 2026 net product revenue rose 106% to $208k. Still a net loss.
Gross profit on product revenues was $57k vs $51k prior year.
Operating expenses were $2.33M vs $1.86M.
Going-concern risk cited. No manufacturing capacity.
Three babesiosis trials underway; ARAKODA approved malaria prevention in 2018.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

60 Degrees Q2 2026 Results Highlight Limited Revenue Growth and Ongoing Losses

Significant Cure Rate Achieved in Babesiosis Study for SXTP